Home Tools
Log in
Cart

c-RET

RET is the receptor for GDNF-family ligands (GFLs).
Cat. No. Product name CAS No. Purity Chemical Structure
T20742 TG-89 936091-56-4 98%
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
T16995 TAS05567 1429038-15-2 98%
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
T10823 Trans-Pralsetinib 2097132-93-7 98%
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound Example 129).
T14928 Agerafenib hydrochloride 1227678-26-3 98%
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
T12598 Pz-1 1800505-64-9 98%
Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
T4301 AD80 1384071-99-1 98%
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
T1792 Regorafenib 755037-03-7 98%
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
T67779 Compound TPX-0046 2411115-73-4 98%
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
T62285 Enbezotinib 2359649-81-1 98%
Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.
T8222 Selpercatinib 2152628-33-4 98%
Selpercatinib is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), r...
T8467 RET V804M-IN-1 2414909-94-5 98%
RET V804M-IN-1 is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).
T2586 Cabozantinib 849217-68-1 98%
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
T6920 ON123300 1357470-29-1 98%
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
T2620 G-749 1457983-28-6 98%
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
T2070 Agerafenib 1188910-76-0 98%
CEP-32496 is a highly potent inhibitor of BRAF.
T3065 TG101209 936091-14-4 98%
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
T9445 Vepafestinib 2129515-96-2 98%
Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].
T2516 Amuvatinib 850879-09-3 98%
Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
T0520 Lenvatinib 417716-92-8 98%
Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
T2094 Danusertib 827318-97-8 98%
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
TG-89
T20742
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
TAS05567
T16995
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
trans-Pralsetinib
T10823
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound Example 129).
Agerafenib hydrochloride
T14928
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
Pz-1
T12598
Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
AD80
T4301
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
Regorafenib
T1792
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
Compound TPX-0046
T67779
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
Enbezotinib
T62285
Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.
Selpercatinib
T8222
Selpercatinib is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), r...
RET V804M-IN-1
T8467
RET V804M-IN-1 is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).
Cabozantinib
T2586
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
ON123300
T6920
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
G-749
T2620
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
Agerafenib
T2070
CEP-32496 is a highly potent inhibitor of BRAF.
TG101209
T3065
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
Vepafestinib
T9445
Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].
Amuvatinib
T2516
Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
Lenvatinib
T0520
Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
Danusertib
T2094
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
1 2